Assessment of Interstitial Lung Disease in Rheumatoid Arthritis by Lung Ultrasound

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

34 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-04

Study Completion Date

2024-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The high resolution chest scan is the gold standard for the screening of interstitial lung disease, but this remains an onerous examination, and irradiating.

Ultrasound could be used to detect these disorders with a very good sensitivity and specificity. This exam offers the advantage of being non radiating, inexpensive, and accessible to the rheumatologist who already uses it in their daily practice.

The investigators want to assess the lung ultrasound performance compared with the gold standard.

Patients will be included during a regular follow-up consultation with their referent rheumatologist. If there is an indication of first line biotherapy or targeted therapy the doctor will propose to the patient to participate in the study, give him the information leaflet, collect orally non-opposition, and will complete a survey for evaluation of the general health and potential risk factors for interstitial lung.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Lung Ultrasound in Screening for Interstitial Lung Disease in Patients With Rheumatoid Arthritis

NCT06531785

Interstitial Lung Disease Rheumatoid Arthritis

COMPLETED

Lung Ultrasound Artefact Analysis for Exclusion of Acute Rejection in Lung Transplant Recipients

NCT04582279

Post-Lung Transplantation Bronchiectasis

RECRUITING NA

Clinical Relevance of Thoracic Echography for the Early Diagnosis of Interstitial Lung Disease in Systemic Scleroderma - Pilot Study

NCT04725786

Systemic Sclerosis

COMPLETED NA

Value of Chest Ultrasonography in ILD Screening

NCT06260930

Interstitial Lung Disease

COMPLETED

A Randomized Controlled Trial of Lung Ultrasound Compared to Chest X-ray for Diagnosing Pneumonia in the Emergency Department

NCT01654887

Pneumonia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Diseases Lung Diseases, Interstitial Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sample population

Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.

Lung sonography

Intervention Type OTHER

Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.

Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lung sonography

Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.

Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women over the age of 18
* With rheumatoid arthritis meeting the criteria ACR (American College of Rheumatology)/ EULAR (EUropean League Against Rheumatism) 2010
* Never received any biotherapy or targeted therapy
* Having an indication of introduction of biotherapy or therapy targeted (JAK inhibitors) (JAK : Janus kinase)

Exclusion Criteria

* Refusal to participate in the study
* Known pulmonary disease that can alter lung interstitium: cardiac decompensation, COPD (chronic obstructive pulmonary disease), thoracic surgery, infection pulmonary
* Patient with respiratory functional signs suggestive of PID (Diffuse interstitial lung disease)
* Patient with signs of cardiac decompensation
* Patient with pulmonary auscultation suggestive of PID
* Pregnant or lactating woman
* Psychiatric pathology seriously hindering understanding
* Difficulty understanding oral French
* Person deprived of liberty or under legal protection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No